Teleflex Receives FDA 510(k) Clearance for ARROW® FlexBlock™ Continuous Peripheral Nerve Block Cathe
Teleflex Receives FDA 510(k) Clearance for ARROW®FlexBlock™Continuous Peripheral Nerve Block Catheter
LIMERICK, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYS: TFX) today announced the ARROW FlexBlock continuous peripheral nerve block catheter has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
The ARROW FlexBlock continuous peripheral nerve block catheter is intended for clinicians who use ultrasound-guidance when placing continuous peripheral nerve block catheters. The echogenic, coil-reinforced FlexBlock catheter body is constructed of polyurethane, and the unique catheter design offers a combination of ultrasound visibility, flexibility, and excellent kink resistance. The FlexBlock catheter's tip design is intended to provide clinicians with a predictable spread of anesthetic.
"Teleflex is pleased to be adding the ARROW FlexBlock catheter to our market-leading1 line of ARROW® StimuCath® continuous peripheral nerve block catheters," said Cary Vance, President, Teleflex Anesthesia and Respiratory. "These products, in addition to the StimuQuik® ECHO peripheral nerve block needles, SureBlock® spinal trays, and the recently 510(k) cleared FlexTip Plus® Multi-Port epidural catheters, give Teleflex a clinically differentiated regional anesthesia product portfolio, designed to meet the needs of anesthesiologists in the field of regional anesthesia and acute pain management."
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,200 people worldwide and serves healthcare providers in more than 130 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Arrow, FlexBlock, FlexTip Plus, StimuCath, StimuQuik, SureBlock, and Teleflex are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.
©2012 Teleflex Incorporated. All rights reserved. 2012-1317.
References:
1. IMS Market Data, Q1 2011
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS:
The article Teleflex Receives FDA 510(k) Clearance for ARROW® FlexBlock™ Continuous Peripheral Nerve Block Catheter originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
